Allergan’s Juvederm gets multi-center trial
This article was originally published in The Gray Sheet
Executive Summary
Allergan's hyaluronic acid dermal filler products Juvederm Ultra and Juvederm Ultra Plus commence a multi-center, open-label trial designed to gain information on physicians' use of the products. FDA approved the Juvederm fillers in June, and the firm plans a January 2007 national launch. The fillers join Allergan's Botox botulinum toxin type A in its portfolio of physician-dispensed facial aesthetics. Allergan acquired the products in March as part of its acquisition of Inamed (1"The Gray Sheet" June 12, 2006, p. 15)...